Key result
Resistant hypertension affects approximately 20% of hypertensive patients and requires careful workup to rule out pseudo-resistance and secondary causes.
This editorial discusses the management of resistant hypertension and the role of decreasing aldosterone effects.
Despite the availability of several medications to treat hypertension, approximately 20% of patients with this condition have apparent resistant hypertension, which is defined as in-office systolic and diastolic blood pressure that is not decreased to less than 130/80 mmHg despite lifestyle measures and treatment with the maximum tolerated doses of three or more drugs, including a diuretic, a renin–angiotensin system blocker, and a calcium-channel blocker.1 Resistant hypertension is associated with an increased risk of premature cardiovascular events.1 The initial workup should rule out pseudo–resistant hypertension with the use of out-of-office blood-pressure measurements, nonadherence to antihypertensive medications, and secondary hypertension.1 Resistant . . .
No takes yet. Share an insight, caveat, or question.
Michel Azizi (2023) conducted an editorial in Resistant hypertension. Resistant hypertension affects approximately 20% of hypertensive patients and requires careful workup to rule out pseudo-resistance and secondary causes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: